Precigen (PGEN) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

PGEN Stock Forecast

Precigen stock forecast is as follows: an average price target of $6.00 (represents a 686.78% upside from PGEN’s last price of $0.76) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.

PGEN Price Target

The average price target for Precigen (PGEN) is $6.00 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $6.00 to $6.00. This represents a potential 686.78% upside from PGEN's last price of $0.76.

PGEN Analyst Ratings

Buy

According to 4 Wall Street analysts, Precigen's rating consensus is 'Buy'. The analyst rating breakdown for PGEN stock is 0 'Strong Buy' (0.00%), 4 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Precigen Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Aug 09, 2022		H.C. Wainwright	$6.00	$2.05	192.68%	686.78%

The latest Precigen stock forecast, released on Aug 09, 2022 by H.C. Wainwright company, set a price target of $6.00, which represents a 192.68% increase from the stock price at the time of the forecast ($2.05), and a 686.78% increase from PGEN last price ($0.76).

Precigen Price Target by Period

	1M	3M	12M
# Anlaysts	-	-	-
Avg Price Target	-	-	-
Last Closing Price	$0.76	$0.76	$0.76
Upside/Downside	-100.00%	-100.00%	-100.00%

In the current month, the average price target of Precigen stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Precigen's last price of $0.76. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Aug 15, 2024	JMP Securities	Market Outperform	Market Outperform	Hold
Aug 15, 2024	H.C. Wainwright	Buy	Buy	Hold
Jun 03, 2024	JMP Securities	Underperform	Underperform	Hold
Jun 03, 2024	Stifel Nicolaus	Market Outperform	Market Outperform	Hold
Nov 18, 2022	Cantor Fitzgerald		Overweight	Initialise
Nov 14, 2022	JMP Securities	Market Outperform	Market Outperform	Hold

Precigen's last stock rating was published by JMP Securities on Aug 15, 2024. The company gave PGEN a "Market Outperform" rating, the same as its previous rate.

Precigen Financial Forecast

Precigen Revenue Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17
Revenue	-	-	-	-	-	-	-	-	-	$16.72M	$1.77M	$1.85M	$1.76M	$16.72M	$2.91M	$32.02M	$24.22M	$21.56M	$33.58M	$24.51M	$19.33M	$23.58M	$30.42M	$29.84M	$8.36M	$23.04M	$35.99M	$23.34M	$43.84M	$53.75M
Avg Forecast	$32.05M	$7.85M	$1.10M	$1.10M	$1.63M	$931.40K	$1.29M	$1.48M	$2.13M	$1.60M	$2.15M	$2.23M	$6.21M	$2.72M	$22.54M	$28.32M	$24.30M	$20.94M	$21.06M	$24.00M	$21.20M	$17.70M	$16.14M	$10.50M	$23.40M	$33.00M	$29.62M	$32.12M	$42.83M	$49.61M
High Forecast	$32.05M	$7.85M	$1.10M	$1.10M	$1.98M	$931.40K	$1.29M	$1.48M	$2.41M	$1.60M	$2.15M	$2.23M	$6.21M	$2.72M	$22.54M	$28.32M	$24.30M	$20.94M	$21.06M	$24.00M	$21.20M	$17.70M	$16.14M	$10.50M	$23.40M	$33.00M	$29.62M	$32.12M	$51.40M	$59.54M
Low Forecast	$32.05M	$7.85M	$1.10M	$1.10M	$1.26M	$931.40K	$1.29M	$1.48M	$1.85M	$1.60M	$2.15M	$2.23M	$6.21M	$2.72M	$22.54M	$28.32M	$24.30M	$20.94M	$21.06M	$24.00M	$21.20M	$17.70M	$16.14M	$10.50M	$23.40M	$33.00M	$29.62M	$32.12M	$34.27M	$39.69M
# Analysts	1	1	1	2	3	1	1	1	3	1	1	1	1	1	1	1	1	1	1	1	10	10	10	10	9	9	9	9	20	15
Surprise %	-	-	-	-	-	-	-	-	-	10.48%	0.82%	0.83%	0.28%	6.15%	0.13%	1.13%	1.00%	1.03%	1.59%	1.02%	0.91%	1.33%	1.89%	2.84%	0.36%	0.70%	1.21%	0.73%	1.02%	1.08%

Precigen's average Quarter revenue forecast for Dec 23 based on 3 analysts is $2.13M, with a low forecast of $1.85M, and a high forecast of $2.41M. PGEN's average Quarter revenue forecast represents a -87.27% decrease compared to the company's last Quarter revenue of $16.72M (Sep 23).

Precigen EBITDA Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17
# Analysts	1	1	1	2	3	1	1	1	3	1	1	1	1	1	1	1	1	1	1	1	10	10	10	10	9	9	9	9	20	15
EBITDA	-	-	-	-	-	-	-	-	-	$-7.64M	$-18.55M	$-22.46M	$-19.81M	$-3.13M	$-20.22M	$-13.47M	$-57.60M	$-21.63M	$-11.92M	$-9.31M	$-33.23M	$-20.80M	$-34.10M	$-46.56M	$-157.82M	$-43.65M	$-28.82M	$-50.40M	$-37.59M	$-24.35M
Avg Forecast	$-28.79M	$-7.05M	$-988.20K	$-988.20K	$-1.46M	$-836.74K	$-1.16M	$-15.01M	$-1.91M	$-1.43M	$-1.93M	$-16.05M	$-1.56B	$-2.48M	$-20.58M	$-17.17M	$-22.19M	$-19.12M	$-19.23M	$-12.04M	$-19.36M	$-16.16M	$-14.73M	$-27.74M	$-21.37M	$-30.13M	$-27.04M	$-37.80M	$-36.71M	$-22.32M
High Forecast	$-28.79M	$-7.05M	$-988.20K	$-988.20K	$-1.13M	$-836.74K	$-1.16M	$-12.01M	$-1.66M	$-1.43M	$-1.93M	$-12.84M	$-1.25B	$-2.48M	$-20.58M	$-13.73M	$-22.19M	$-19.12M	$-19.23M	$-9.63M	$-19.36M	$-16.16M	$-14.73M	$-22.19M	$-21.37M	$-30.13M	$-27.04M	$-30.24M	$-29.37M	$-17.86M
Low Forecast	$-28.79M	$-7.05M	$-988.20K	$-988.20K	$-1.78M	$-836.74K	$-1.16M	$-18.01M	$-2.17M	$-1.43M	$-1.93M	$-19.26M	$-1.87B	$-2.48M	$-20.58M	$-20.60M	$-22.19M	$-19.12M	$-19.23M	$-14.45M	$-19.36M	$-16.16M	$-14.73M	$-33.29M	$-21.37M	$-30.13M	$-27.04M	$-45.36M	$-44.05M	$-26.79M
Surprise %	-	-	-	-	-	-	-	-	-	5.33%	9.61%	1.40%	0.01%	1.26%	0.98%	0.78%	2.60%	1.13%	0.62%	0.77%	1.72%	1.29%	2.31%	1.68%	7.39%	1.45%	1.07%	1.33%	1.02%	1.09%

undefined analysts predict PGEN's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Precigen's previous annual EBITDA (undefined) of $NaN.

Precigen Net Income Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17
# Analysts	1	1	1	2	3	1	1	1	3	1	1	1	1	1	1	1	1	1	1	1	10	10	10	10	9	9	9	9	20	15
Net Income	-	-	-	-	-	-	-	-	-	$87.38M	$-20.32M	$-22.73M	$-22.18M	$-7.64M	$-26.06M	$-19.25M	$-25.35M	$-29.76M	$-20.05M	$-17.32M	$-41.66M	$-29.51M	$-43.35M	$-56.00M	$-169.22M	$-53.63M	$-38.77M	$-60.71M	$-41.99M	$-31.40M
Avg Forecast	$-2.76M	$-13.79M	$-16.55M	$-15.63M	$-18.21M	$-23.80M	$-26.40M	$-20.71M	$-21.80M	$-22.07M	$-27.73M	$-22.15M	$-1.61B	$-34.07M	$-36.59M	$-23.69M	$-30.28M	$-37.01M	$-31.34M	$-22.41M	$-42.90M	$-35.33M	$-34.07M	$-33.37M	$-62.20M	$-60.57M	$-74.45M	$-45.53M	$-41.00M	$-28.78M
High Forecast	$-2.76M	$-13.79M	$-16.55M	$-13.03M	$-18.21M	$-23.80M	$-26.40M	$-16.57M	$-19.07M	$-22.07M	$-27.73M	$-17.72M	$-1.29B	$-34.07M	$-36.59M	$-18.95M	$-30.28M	$-37.01M	$-31.34M	$-17.92M	$-42.90M	$-35.33M	$-34.07M	$-26.69M	$-62.20M	$-60.57M	$-74.45M	$-36.43M	$-32.80M	$-23.03M
Low Forecast	$-2.76M	$-13.79M	$-16.55M	$-18.24M	$-21.24M	$-23.80M	$-26.40M	$-24.86M	$-21.80M	$-22.07M	$-27.73M	$-26.58M	$-1.93B	$-34.07M	$-36.59M	$-28.43M	$-30.28M	$-37.01M	$-31.34M	$-26.89M	$-42.90M	$-35.33M	$-34.07M	$-40.04M	$-62.20M	$-60.57M	$-74.45M	$-54.64M	$-49.20M	$-34.54M
Surprise %	-	-	-	-	-	-	-	-	-	-3.96%	0.73%	1.03%	0.01%	0.22%	0.71%	0.81%	0.84%	0.80%	0.64%	0.77%	0.97%	0.84%	1.27%	1.68%	2.72%	0.89%	0.52%	1.33%	1.02%	1.09%

Precigen's average Quarter net income forecast for Dec 23 is $-21.80M, with a range of $-21.80M to $-19.07M. PGEN's average Quarter net income forecast represents a -124.95% decrease compared to the company's last Quarter net income of $87.38M (Sep 23).

Precigen SG&A Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17
# Analysts	1	1	1	2	3	1	1	1	3	1	1	1	1	1	1	1	1	1	1	1	10	10	10	10	9	9	9	9	20	15
SG&A	-	-	-	-	-	-	-	-	-	$10.14M	$9.32M	$11.64M	$11.51M	$10.14M	$12.67M	$19.58M	$16.76M	$18.66M	$20.00M	$18.70M	$27.65M	$22.30M	$18.74M	$23.02M	$21.03M	$24.74M	$21.48M	$33.59M	$39.74M	$35.14M
Avg Forecast	$70.45M	$17.25M	$2.42M	$2.42M	$3.57M	$2.05M	$2.84M	$3.25M	$4.68M	$3.51M	$4.73M	$4.89M	$13.65M	$5.56M	$46.03M	$24.09M	$49.64M	$42.77M	$43.02M	$49.02M	$43.30M	$36.16M	$32.95M	$21.44M	$47.79M	$67.40M	$60.49M	$25.20M	$38.80M	$32.21M
High Forecast	$70.45M	$17.25M	$2.42M	$2.42M	$4.36M	$2.05M	$2.84M	$3.25M	$5.30M	$3.51M	$4.73M	$4.89M	$13.65M	$5.56M	$46.03M	$28.91M	$49.64M	$42.77M	$43.02M	$49.02M	$43.30M	$36.16M	$32.95M	$21.44M	$47.79M	$67.40M	$60.49M	$30.23M	$46.56M	$38.65M
Low Forecast	$70.45M	$17.25M	$2.42M	$2.42M	$2.76M	$2.05M	$2.84M	$3.25M	$4.06M	$3.51M	$4.73M	$4.89M	$13.65M	$5.56M	$46.03M	$19.27M	$49.64M	$42.77M	$43.02M	$49.02M	$43.30M	$36.16M	$32.95M	$21.44M	$47.79M	$67.40M	$60.49M	$20.16M	$31.04M	$25.77M
Surprise %	-	-	-	-	-	-	-	-	-	2.89%	1.97%	2.38%	0.84%	1.82%	0.28%	0.81%	0.34%	0.44%	0.46%	0.38%	0.64%	0.62%	0.57%	1.07%	0.44%	0.37%	0.36%	1.33%	1.02%	1.09%

Precigen's average Quarter SG&A projection for Dec 23 is $4.68M, based on 3 Wall Street analysts, with a range of $4.06M to $5.30M. The forecast indicates a -53.82% fall compared to PGEN last annual SG&A of $10.14M (Sep 23).

Precigen EPS Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17
# Analysts	1	1	1	2	3	1	1	1	3	1	1	1	1	1	1	1	1	1	1	1	10	10	10	10	9	9	9	9	20	15
EPS	-	-	-	-	-	-	-	-	-	-	$-0.08	$-0.10	$-0.11	$-0.04	$-0.13	$-0.10	$-0.13	$-0.15	$-0.10	$-0.09	$-0.23	$-0.18	$-0.26	$-0.35	$-1.09	$-0.35	$-0.25	$-0.40	$-0.33	$-0.26
Avg Forecast	$-0.01	$-0.05	$-0.06	$-0.06	$-0.07	$-0.09	$-0.10	$-0.09	$-0.08	$-0.08	$-0.10	$-0.09	$-0.10	$-0.14	$-0.14	$-0.10	$-0.12	$-0.15	$-0.12	$-0.13	$-0.17	$-0.14	$-0.14	$-0.24	$-0.25	$-0.24	$-0.29	$-0.32	$-0.19	$-0.22
High Forecast	$-0.01	$-0.05	$-0.06	$-0.05	$-0.07	$-0.09	$-0.10	$-0.09	$-0.07	$-0.08	$-0.10	$-0.09	$-0.10	$-0.14	$-0.14	$-0.10	$-0.12	$-0.15	$-0.12	$-0.13	$-0.17	$-0.14	$-0.14	$-0.24	$-0.25	$-0.24	$-0.29	$-0.32	$-0.15	$-0.18
Low Forecast	$-0.01	$-0.05	$-0.06	$-0.07	$-0.08	$-0.09	$-0.10	$-0.09	$-0.08	$-0.08	$-0.10	$-0.09	$-0.10	$-0.14	$-0.14	$-0.10	$-0.12	$-0.15	$-0.12	$-0.13	$-0.17	$-0.14	$-0.14	$-0.24	$-0.25	$-0.24	$-0.29	$-0.32	$-0.22	$-0.26
Surprise %	-	-	-	-	-	-	-	-	-	-	0.81%	1.07%	1.10%	0.28%	0.90%	0.92%	1.08%	1.02%	0.81%	0.69%	1.35%	1.29%	1.93%	1.46%	4.42%	1.46%	0.85%	1.25%	1.74%	1.18%

According to undefined Wall Street analysts, Precigen's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to PGEN previous annual EPS of $NaN (undefined).

Precigen Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
PGEN	Precigen	$0.69	$6.00	769.57%	Buy
ADAP	Adaptimmune Therapeutics	$0.60	$4.00	566.67%	Buy
INZY	Inozyme Pharma	$2.94	$16.00	444.22%	Buy
AFMD	Affimed	$1.51	$7.50	396.69%	Buy
SGMO	Sangamo Therapeutics	$2.82	$12.00	325.53%	Buy
AGEN	Agenus	$2.96	$7.33	147.64%	Hold
SNDX	Syndax Pharmaceuticals	$13.63	$31.67	132.36%	Buy
ZNTL	Zentalis Pharmaceuticals	$3.13	$7.00	123.64%	Buy
DAWN	Day One Biopharmaceuticals	$12.64	$24.00	89.87%	Buy
LPTX	Leap Therapeutics	$3.11	$5.50	76.85%	Buy
CRVS	Corvus Pharmaceuticals	$7.39	$12.50	69.15%	Buy
IMMP	Immutep	$2.13	$3.50	64.32%	Buy
EWTX	Edgewise Therapeutics	$30.17	$46.25	53.30%	Buy
PTGX	Protagonist Therapeutics	$40.69	$57.33	40.89%	Buy
CRMD	CorMedix	$8.54	$9.00	5.39%	Buy

PGEN Forecast FAQ

Is Precigen a good buy?

Yes, according to 4 Wall Street analysts, Precigen (PGEN) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 4 'Buy' recommendations, accounting for 100.00% of PGEN's total ratings.

What is PGEN's price target?

Precigen (PGEN) average price target is $6 with a range of $6 to $6, implying a 686.78% from its last price of $0.763. The data is based on 4 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Precigen stock go up soon?

According to Wall Street analysts' prediction for PGEN stock, the company can go up by 686.78% (from the last price of $0.763 to the average price target of $6), up by 686.78% based on the highest stock price target, and up by 686.78% based on the lowest stock price target.

Can Precigen stock reach $1?

PGEN's average twelve months analyst stock price target of $6 supports the claim that Precigen can reach $1 in the near future.

What are Precigen's analysts' financial forecasts?

Precigen's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $5.33M (high $5.68M, low $4.96M), average EBITDA is $-18.464M (high $-15.13M, low $-21.787M), average net income is $-89.119M (high $-84.976M, low $-96.296M), average SG&A $11.71M (high $12.5M, low $10.9M), and average EPS is $-0.336 (high $-0.336, low $-0.347). PGEN's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $42.1M (high $42.1M, low $42.1M), average EBITDA is $-37.821M (high $-37.821M, low $-37.821M), average net income is $-48.739M (high $-46.134M, low $-51.345M), average SG&A $92.54M (high $92.54M, low $92.54M), and average EPS is $-0.177 (high $-0.167, low $-0.186).

Did the PGEN's actual financial results beat the analysts' financial forecasts?

Based on Precigen's last annual report (Dec 2022), the company's revenue was $26.91M, which missed the average analysts forecast of $59.79M by -55.00%. Apple's EBITDA was $-72.072M, missing the average prediction of $-1.601B by -95.50%. The company's net income was $-79.777M, missing the average estimation of $-1.704B by -95.32%. Apple's SG&A was $48.01M, missing the average forecast of $89.33M by -46.26%. Lastly, the company's EPS was $-0.4, missing the average prediction of $-0.485 by -17.53%. In terms of the last quarterly report (Sep 2023), Precigen's revenue was $16.72M, beating the average analysts' forecast of $1.6M by 947.88%. The company's EBITDA was $-7.644M, beating the average prediction of $-1.434M by 433.20%. Precigen's net income was $87.38M, missing the average estimation of $-22.07M by -495.91%. The company's SG&A was $10.14M, beating the average forecast of $3.51M by 188.99%. Lastly, the company's EPS was $0, missing the average prediction of $-0.08 by -100.00%